Equity Details
Price & Market Data
Price: $83.55
Daily Change: -$0.55 / 0.66%
Daily Range: $81.90 - $84.69
Market Cap: $6,872,621,568
Daily Volume: 377,263
Performance Metrics
1 Week: 1.02%
1 Month: -5.63%
3 Months: 5.11%
6 Months: 42.43%
1 Year: 159.7%
YTD: 7.38%
About Kymera Therapeutics, Inc. (KYMR)
Data on Kymera Therapeutics, Inc. (KYMR). Price: 83.55, daily change: -$0.55 / 0.66%. Market cap: 6,872,621,568. Performance YTD and 1-year.
Company Details
Employees: 238
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.